Advertisement

Little effect of 0.01% atropine eye drops as used in myopia prevention on the pattern electroretinogram

  • Lisa-Marie AndersEmail author
  • Sven P. Heinrich
  • Wolf A. Lagrèze
  • Lutz Joachimsen
Original Research Article

Abstract

Purpose

Daily administration of 0.01% atropine eye drops is a promising approach for myopia control. The mechanism of action is believed to involve the dopaminergic system of the retina, triggering an increased release of dopamine. Previous studies in psychiatric condition such as major depression suggest that pattern electroretinogram (PERG) amplitudes are modulated by changes in retinal dopamine. It is thus plausible that atropine eye drops could have an effect on PERG amplitudes. The present study was designed to test this, assessing the difference in amplitude between contrast levels and the ratio of amplitudes between check sizes as primary endpoints.

Methods

We included 14 participants with no more than ± 2 diopters of ametropia and visual acuity of at least 1.0. One eye was chosen randomly in each participant for atropine application (14 days, one drop of 0.01% atropine solution once daily before bedtime). We recorded two sets of steady-state PERG recordings: one with different contrasts (25% and 98%) and one with different check sizes (0.8° and 17°). Near-point distance, near visual acuity, and pupil diameter were measured additionally.

Results

The recordings to different contrasts did not show atropine-related changes of PERG amplitude. A small increase by 6% of the amplitude difference between contrast levels with atropine application was not significant (p = 0.08). Raw amplitudes in the check size condition increased with atropine by 17% (p < 0.01) and 10% (p < 0.03) for small and large checks, respectively, without a significant concomitant effect on the amplitude ratio. Pupil size was significantly affected (median increase 0.5 mm, p < 0.002). However, neither of the experimental conditions was associated with a significant correlation between pupil size and PERG effects.

Conclusion

The effects on PERG primary endpoints after the 14-day period of atropine administration were small, especially compared to effect sizes in major depression, and statistically insignificant. Effects on raw amplitude were inconsistent. The present results suggest that retinal processing as reflected by PERG does not sizably change following a treatment regimen with atropine that is typical for myopia control.

Keywords

Pattern electroretinogram Atropine Myopia Dopamine 

Notes

Acknowledgements

We are grateful to numerous members of our department with an interest in the topic who stimulated and encouraged the work presented here. Most of these individuals also volunteered as participants in this self-experimentation study. In order to ensure the protection of their personal data, we do not list them by name.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statement on the welfare of animals

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Lagrèze WA, Joachimsen L, Schaeffel F (2017) Gegenwärtiger Stand der Empfehlungen zur Minderung von Myopieprogression. Ophthalmologe 114:24–29.  https://doi.org/10.1007/s00347-016-0346-1 CrossRefGoogle Scholar
  2. 2.
    Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L (2017) Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA Ophthalmol 135:624–630.  https://doi.org/10.1001/jamaophthalmol.2017.1091 CrossRefGoogle Scholar
  3. 3.
    Schwahn HN, Kaymak H, Schaeffel F (2000) Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci 17:165–176CrossRefGoogle Scholar
  4. 4.
    Cohen Y, Peleg E, Belkin M, Polat U, Solomon AS (2012) Ambient illuminance, retinal dopamine release and refractive development in chicks. Exp Eye Res 103:33–40.  https://doi.org/10.1016/j.exer.2012.08.004 CrossRefGoogle Scholar
  5. 5.
    Megaw PL, Boelen MG, Morgan IG, Boelen MK (2006) Diurnal patterns of dopamine release in chicken retina. Neurochem Int 48:17–23.  https://doi.org/10.1016/j.neuint.2005.08.004 CrossRefGoogle Scholar
  6. 6.
    Schaeffel F (2017) Biologische Mechanismen der Myopie. Ophthalmologe 114:5–19.  https://doi.org/10.1007/s00347-016-0388-4 CrossRefGoogle Scholar
  7. 7.
    Stone RA, Lin T, Laties AM, Iuvone PM (1989) Retinal dopamine and form-deprivation myopia. Proc Natl Acad Sci USA 86:704–706CrossRefGoogle Scholar
  8. 8.
    Zhou X, Pardue MT, Iuvone PM, Qu J (2017) Dopamine signaling and myopia development: what are the key challenges. Prog Retin Eye Res 61:60–71.  https://doi.org/10.1016/j.preteyeres.2017.06.003 CrossRefGoogle Scholar
  9. 9.
    Ashby R, Ohlendorf A, Schaeffel F (2009) The effect of ambient illuminance on the development of deprivation myopia in chicks. Investig Ophthalmol Vis Sci 50:5348–5354.  https://doi.org/10.1167/iovs.09-3419 CrossRefGoogle Scholar
  10. 10.
    Iuvone PM, Tigges M, Stone RA, Lambert S, Laties AM (1991) Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia. Investig Ophthalmol Vis Sci 32:1674–1677Google Scholar
  11. 11.
    Ohngemach S, Hagel G, Schaeffel F (1997) Concentrations of biogenic amines in fundal layers in chickens with normal visual experience, deprivation, and after reserpine application. Vis Neurosci 14:493–505CrossRefGoogle Scholar
  12. 12.
    Schaeffel F, Bartmann M, Hagel G, Zrenner E (1995) Studies on the role of the retinal dopamine/melatonin system in experimental refractive errors in chickens. Vis Res 35:1247–1264CrossRefGoogle Scholar
  13. 13.
    Nickla DL, Totonelly K, Dhillon B (2010) Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks. Exp Eye Res 91:715–720.  https://doi.org/10.1016/j.exer.2010.08.021 CrossRefGoogle Scholar
  14. 14.
    Rohrer B, Spira AW, Stell WK (1993) Apomorphine blocks form-deprivation myopia in chickens by a dopamine D2-receptor mechanism acting in retina or pigmented epithelium. Vis Neurosci 10:447–453CrossRefGoogle Scholar
  15. 15.
    Domenici L, Trimarchi C, Piccolino M, Fiorentini A, Maffei L (1985) Dopaminergic drugs improve human visual contrast sensitivity. Hum Neurobiol 4:195–197Google Scholar
  16. 16.
    Bubl E, Kern E, Ebert D, Bach M, Tebartz van Elst L (2010) Seeing gray when feeling blue? Depression can be measured in the eye of the diseased. Biol Psychiatry 68:205–208.  https://doi.org/10.1016/j.biopsych.2010.02.009 CrossRefGoogle Scholar
  17. 17.
    Bubl E, Kern E, Ebert D, Riedel A, Tebartz van Elst L, Bach M (2015) Retinal dysfunction of contrast processing in major depression also apparent in cortical activity. Eur Arch Psychiatry Clin Neurosci 265:343–350.  https://doi.org/10.1007/s00406-014-0573-x CrossRefGoogle Scholar
  18. 18.
    Bach M, Brigell MG, Hawlina M, Holder GE, Johnson MA, McCulloch DL, Meigen T, Viswanathan S (2012) ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol 126:1–7.  https://doi.org/10.1007/s10633-012-9353-y CrossRefGoogle Scholar
  19. 19.
    Djamgoz MB, Hankins MW, Hirano J, Archer SN (1997) Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vis Res 37:3509–3529.  https://doi.org/10.1016/S0042-6989(97)00129-6 CrossRefGoogle Scholar
  20. 20.
    Schwitzer T, Lavoie J, Giersch A, Schwan R, Laprevote V (2015) The emerging field of retinal electrophysiological measurements in psychiatric research: a review of the findings and the perspectives in major depressive disorder. J Psychiatr Res 70:113–120.  https://doi.org/10.1016/j.jpsychires.2015.09.003 CrossRefGoogle Scholar
  21. 21.
    Schaeffel F (2011) Myopie Update 2011. Klin Monatsbl Augenheilkd 228:754–761.  https://doi.org/10.1055/s-0031-1281584 CrossRefGoogle Scholar
  22. 22.
    Feldkaemper M, Schaeffel F (2013) An updated view on the role of dopamine in myopia. Exp Eye Res 114:106–119.  https://doi.org/10.1016/j.exer.2013.02.007 CrossRefGoogle Scholar
  23. 23.
    Bach M, Hiss P, Röver J (1988) Check-size specific changes of pattern electroretinogram in patients with early open-angle glaucoma. Doc Ophthalmol 69:315–322CrossRefGoogle Scholar
  24. 24.
    Bach M, Hoffmann MB (2008) Update on the pattern electroretinogram in glaucoma. Optom Vis Sci 85:386–395.  https://doi.org/10.1097/OPX.0b013e318177ebf3 CrossRefGoogle Scholar
  25. 25.
    Dawson WW, Trick GL, Litzkow CA (1979) Improved electrode for electroretinography. Investig Ophthalmol Vis Sci 18:988–991Google Scholar
  26. 26.
    Bach M, Meigen T (1999) Do’s and don’ts in Fourier analysis of steady-state potentials. Doc Ophthalmol 99:69–82CrossRefGoogle Scholar
  27. 27.
    Westheimer G (2008) Directional sensitivity of the retina: 75 years of Stiles–Crawford effect. Proc R Soc B Biol Sci 275:2777–2786.  https://doi.org/10.1098/rspb.2008.0712 CrossRefGoogle Scholar
  28. 28.
    Langheinrich T, Tebartz van Elst L, Lagrèze WA, Bach M, Lücking CH, Greenlee MW (2000) Visual contrast response functions in Parkinson’s disease: evidence from electroretinograms, visually evoked potentials and psychophysics. Clin Neurophysiol 111:66–74CrossRefGoogle Scholar
  29. 29.
    Tebartz van Elst L, Greenlee MW, Foley JM, Lücking CH (1997) Contrast detection, discrimination and adaptation in patients with Parkinson’s disease and multiple system atrophy. Brain J Neurol 120(Pt 12):2219–2228CrossRefGoogle Scholar
  30. 30.
    Luu CD, Lau AMI, Koh AHC, Tan D (2005) Multifocal electroretinogram in children on atropine treatment for myopia. Br J Ophthalmol 89:151–153.  https://doi.org/10.1136/bjo.2004.045526 CrossRefGoogle Scholar
  31. 31.
    Pineles SL, Kraker RT, VanderVeen DK, Hutchinson AK, Galvin JA, Wilson LB, Lambert SR (2017) Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology. Ophthalmology 124:1857–1866.  https://doi.org/10.1016/j.ophtha.2017.05.032 CrossRefGoogle Scholar
  32. 32.
    Chia A, Li W, Tan D, Luu CD (2013) Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study. Doc Ophthalmol 126:177–186.  https://doi.org/10.1007/s10633-012-9372-8 CrossRefGoogle Scholar
  33. 33.
    Loughman J, Flitcroft DI (2016) The acceptability and visual impact of 0.01% atropine in a Caucasian population. Br J Ophthalmol 100:1525–1529.  https://doi.org/10.1136/bjophthalmol-2015-307861 CrossRefGoogle Scholar
  34. 34.
    Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M (1987) Visual dysfunction in Parkinson’s disease. Loss in spatiotemporal contrast sensitivity. Brain J Neurol 110(Pt 6):1675–1698CrossRefGoogle Scholar
  35. 35.
    Ikeda H, Head GM, Ellis CJ (1994) Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson’s disease and a follow up study. Vis Res 34:2629–2638CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Eye Center, Medical CenterUniversity of FreiburgFreiburgGermany
  2. 2.Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations